Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/30/2025

Management of Hives in a Patient on Augmentin

Classification and Assessment

  • The severity of urticaria can be classified as mild (less than 3 hives), moderate (3-10 hives), or severe (generalized involvement) 1

Treatment Based on Severity

  • For mild to moderate hives, the American Academy of Allergy, Asthma, and Immunology recommends starting a non-sedating H1 antihistamine immediately, such as cetirizine 10 mg daily, loratadine 10 mg daily, fexofenadine 180 mg daily, or levocetirizine 5 mg daily 1, 2, 3
  • If inadequate response within 24-48 hours, the guideline suggests increasing the antihistamine dose up to 4 times the standard dose (e.g., cetirizine 40 mg daily) 1, 3
  • For severe or generalized hives, oral corticosteroids such as prednisone 0.5-1 mg/kg/day (typically 40-60 mg for adults) for 3-5 days may be administered 3

Critical Management Points

  • The patient should be warned about recurrent urticaria over the next 1-2 days even after stopping the medication, which is expected and does not indicate treatment failure 1, 4, 5
  • The American Academy of Allergy, Asthma, and Immunology recommends documenting the allergy prominently in the medical record as "penicillin allergy" or specifically "amoxicillin/Augmentin allergy" 4, 5

Follow-Up and Patient Education

  • The Mayo Clinic recommends providing an emergency action plan that includes instructions to seek immediate care if breathing difficulty, widespread urticaria, or facial/throat swelling develops 6
  • Consider prescribing an epinephrine auto-injector if the patient had moderate-to-severe urticaria, as this indicates higher risk for future severe reactions 6, 5
  • Schedule follow-up in 3-5 days to ensure complete resolution of hives and adequate symptom control 1

Treatment of Allergic Reaction with Hives and No Airway Compromise

Adjunctive Therapy for Enhanced Control

  • The American Academy of Allergy, Asthma, and Immunology recommends adding an H2 antihistamine, such as ranitidine 1-2 mg/kg per dose, maximum 75-150 mg, twice daily for 2-3 days, to enhance control of urticaria symptoms 7, 8, 9
  • The American Academy of Allergy, Asthma, and Immunology suggests considering oral corticosteroids, such as prednisone 0.5-1 mg/kg daily, for 2-3 days, for more severe or generalized hives 7, 8, 9

When to Consider Epinephrine

  • The American Academy of Allergy, Asthma, and Immunology states that epinephrine is not indicated for isolated urticaria without systemic symptoms, but is first-line treatment for anaphylaxis, defined by signs including respiratory symptoms, hypotension, gastrointestinal symptoms, or airway compromise 7, 8, 9

Discharge Planning

  • The American Academy of Allergy, Asthma, and Immunology recommends continuing H1 antihistamine every 6 hours for 2-3 days, and H2 antihistamine twice daily for 2-3 days, after discharge 7, 8, 9
  • The American Academy of Allergy, Asthma, and Immunology suggests continuing corticosteroid daily for 2-3 days if initiated, and considering referral to an allergist for identification of triggering allergen and long-term management 7, 8, 9

Common Pitfalls to Avoid

  • The American Academy of Allergy, Asthma, and Immunology advises against administering epinephrine for isolated urticaria without signs of anaphylaxis, as this represents overtreatment and unnecessary risk 7

REFERENCES

1

Urticaria Management and Treatment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Management of Hypersensitivity Reactions to Simvastatin [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Treatment of Hives After Stopping Quetiapine [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

work group report: oral food challenge testing. [LINK]

Journal of Allergy and Clinical Immunology, 2009

5

work group report: oral food challenge testing. [LINK]

Journal of Allergy and Clinical Immunology, 2009